These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. Zhang L; Zhou Q Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer. Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050 [TBL] [Abstract][Full Text] [Related]
7. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Geng N; Su J; Liu Z; Ding C; Xie S; Hu W Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Aydin D; Bilici A; Yavuzer D; Kefeli U; Tan A; Ercelep O; Mert A; Yuksel S; Ozcelik M; Isik D; Surmeli H; Odabasi H; Aliustaoglu M Clin Transl Oncol; 2015 Aug; 17(8):604-11. PubMed ID: 25786367 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. Califano D; Gallo D; Rampioni Vinciguerra GL; De Cecio R; Arenare L; Signoriello S; Russo D; Ferrandina G; Citron F; Losito NS; Gargiulo P; Simeon V; Scambia G; Cecere SC; Montella M; Colombo N; Tognon G; Bignotti E; Zannoni GF; Canzonieri V; Ciucci A; Spina A; Scognamiglio G; Del Sesto M; Schettino C; Piccirillo MC; Perrone F; Chiodini P; Pignata S; Baldassarre G Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680301 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207 [TBL] [Abstract][Full Text] [Related]
11. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Hedemann N; Rogmans C; Sebens S; Wesch D; Reichert M; Schmidt-Arras D; Oberg HH; Pecks U; van Mackelenbergh M; Weimer J; Arnold N; Maass N; Bauerschlag DO Oncotarget; 2018 Mar; 9(22):16043-16058. PubMed ID: 29662625 [TBL] [Abstract][Full Text] [Related]
12. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703 [TBL] [Abstract][Full Text] [Related]
13. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Shou ZX; Jin X; Zhao ZS Ann Surg; 2012 Dec; 256(6):1014-22. PubMed ID: 22668812 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of ADAM17 in human gastric cancer. Zhang TC; Zhu WG; Huang MD; Fan RH; Chen XF Med Oncol; 2012 Dec; 29(4):2684-90. PubMed ID: 22139867 [TBL] [Abstract][Full Text] [Related]
16. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Daniele G; Lorusso D; Scambia G; Cecere SC; Nicoletto MO; Breda E; Colombo N; Artioli G; Cannella L; Lo Re G; Raspagliesi F; Maltese G; Salutari V; Ferrandina G; Greggi S; Baldoni A; Bergamini A; Piccirillo MC; Tognon G; Floriani I; Signoriello S; Perrone F; Pignata S Gynecol Oncol; 2017 Feb; 144(2):256-259. PubMed ID: 27993479 [TBL] [Abstract][Full Text] [Related]
17. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087 [TBL] [Abstract][Full Text] [Related]
18. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma. Xu Q; Ying M; Chen G; Lin A; Xie Y; Ohara N; Zhou D Tumour Biol; 2014 Aug; 35(8):7575-86. PubMed ID: 24793016 [TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199 [TBL] [Abstract][Full Text] [Related]